 
            IndraLab
Statements
                                      reach
                                
                                  
                                
                                
          
          
                                  "As the heterozygous 304Q model is characterized by an increase in plasma NfL at 6 months prior to ataxia symptom onset (Wilke et al., 2020b), a deeper understanding of pre-symptomatic NfL increases in the YACQ84 SCA3 mouse model would establish opportunity for preclinical studies to use NfL as a pre-symptomatic biomarker.Cohesively, we provide evidence of NfL as a biomarker in the YACQ84 mouse, highlighting the onset and progressive increases in NfL, as well as corresponding behavioral symptoms over time."
          
                              
          
                               
                            
                                      reach
                                
                                  
                                
                                
          
          
                                  "As the heterozygous 304Q model is characterized by an increase in plasma NfL at 6 months prior to ataxia symptom onset (Wilke et al., 2020b), a deeper understanding of pre-symptomatic NfL increases in the YACQ84 SCA3 mouse model would establish opportunity for preclinical studies to use NfL as an pre-symptomatic biomarker prior to disease onset.Cohesively, we provide significant natural history of NfL as a biomarker in the YACQ84 mouse, highlighting onset and progressive increases of NfL and behavioral symptoms over time."